Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05243966 · ClinicalTrials.gov registry record
Myriad™ Augmented Soft Tissue Reconstruction Registry
A clinical trial of Hidradenitis Suppurativa and Pressure Injury, sponsored by Aroa Biosurgery Limited.
- Recruiting
- Registry status
- 800
- Enrollment target
- 13
- Study locations
NCT05243966: Recruiting study of Hidradenitis Suppurativa and Pressure Injury, sponsored by Aroa Biosurgery Limited.
NCT05243966 is a study of Hidradenitis Suppurativa and Pressure Injury that is actively recruiting participants, run by Aroa Biosurgery Limited. The registered enrollment target is 800 participants, above the 583-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (37% higher). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05243966, a study of Hidradenitis Suppurativa and Pressure Injury, is actively recruiting participants, sponsored by Aroa Biosurgery Limited.
- RECRUITING
- Registry status
- 800 participants
- Enrollment target
- 13
- Study locations
Study Summary
This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll participants who are undergoing a surgical procedure, where the attending physician will use Myriad™ as part of the surgical intervention.
Primary Outcome
Nature, frequency, and severity of adverse events
Conditions Studied
Interventions
- DEVICE Myriad Matrix™ and Myriad Morcells™
Study Locations (13)
Florida
- Associates in Medicine & Surgery - Fort Myers
- Asencion Sacred Heart - Pensacola
Louisiana
- University Medical Center - New Orleans
- Ochsner Baptist Medical Center - New Orleans
Pennsylvania
- Lancaster General Hospital - Lancaster
- Tower Health Reading Hospital - West Reading
California
- Surgery Group LA - Los Angeles
Georgia
- Northeast Georgia Medical Center, Inc. - Gainesville
Maryland
- Sinai Hospital of Baltimore - Baltimore
New York
- Nuvance Health Vassar Brothers Medical Center - Poughkeepsie
North Carolina
- Moses H Cone Memorial Hospital Operating Corporation - Greensboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2022-01-10 |
| Est. Completion | 2029-01 |
What NCT05243966 shows while recruiting
NCT05243966 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 583-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (37% higher).
The record links to 7 conditions, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Myriad Matrix™ and Myriad Morcells™ is the first listed.
NCT05243966 lists 13 locations in 10 states (Florida, Louisiana, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT05243966 about?
NCT05243966 is a clinical study titled "Myriad™ Augmented Soft Tissue Reconstruction Registry". This is an observational study designed to evaluate the safety and clinical outcomes of Myriad™ in soft tissue reconstruction procedures. The study will enroll participants who are undergoing a surgical procedure, where the attending physician will use Myriad™ as part of the surgical intervention.
What is the current status of trial NCT05243966?
This trial is currently recruiting. The enrollment target is 800 participants. The study started on 2022-01-10. Estimated completion is 2029-01.
What conditions does trial NCT05243966 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa, Pressure Injury, Anal Fistula, Necrotizing Soft Tissue Infection, Lower Extremity Wound.
What interventions are being tested in trial NCT05243966?
The interventions under investigation include: Myriad Matrix™ and Myriad Morcells™ (DEVICE).
Who is sponsoring clinical trial NCT05243966?
This trial is sponsored by Aroa Biosurgery Limited, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05243966 being conducted?
This trial has 13 study locations across California, Florida, Georgia, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05243966's enrollment target sits among peer trials
800 6th of 52 higher than 47 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Aviclear for Hidradenitis Suppurativa (HS)
RECRUITING · NA
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI